1. An innovative berberine formulation is able to improve bbr bioavailability and the lipid and glycemic profile in HFD-fed mice. (August 2022) Authors: Lupo, M.G.; Panighel, G.; Ferrarese, I.; Brilli, E.; Tarantino, G.; Dall'Acqua, S.; Ferri, N. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ANGPTL3 induces a proinflammatory response in THP-1 derived macrophages. (August 2022) Authors: Rossi, I.; Milani, I.; Lupo, M.G.; Ferri, N. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Deciphering the molecular mechanisms underlying the increase in PCSK9 plasma levels in response to anti-PCSK9 mabs: In vitro study in human hepatoma-derived Huh7 cells. (August 2022) Authors: Lupo, M.G.; Panighel, G.; Ferrarese, I.; Zimetti, F.; Adorni, M.P.; Dall'Acqua, S.; Ferri, N. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effects on lipids and pharmacokinetics parameters of PCSK9 mabs in a real life setting high CV risk patients. (August 2022) Authors: Trevisin, M.; Zambon, A.; Zambon, S.; Giammanco, A.; Cefalù, A.B.; Averna, M.; Lupo, M.G.; Ferri, N. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evolocumab and alirocumab increases total PCSK9 plasma levels in hypocholesterolemic patients: Investigation of the basic molecular mechanisms. (August 2021) Authors: Ferri, N.; Lupo, M.G.; Trevisin, M.; Zambon, S.; Zambon, A. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Identification of a new class of small molecule proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. (December 2020) Authors: Ferri, N.; Lupo, M.G.; Radi, M.; Lebrun, J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Leaf extract of morus alba reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line. (August 2018) Authors: Ferri, N.; Lupo, M.G.; Marchianó, S.; Corsini, A. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pcsk9 9 Induces Vascular Calcification Under Uremic Conditions: In Vitro And In Vivo Study. (August 2019) Authors: Ferri, N.; Lupo, M.G.; Poggio, P.; Camera, M.; Faggin, E.; Rattazzi, M. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PCSK9 stimulates vascular calcification by increasing pro-calcific factors and decreasing anti-calcific modulators in vascular smooth muscle cells under uremic conditions. (August 2021) Authors: Lupo, M.G.; Baragetti, A.; Rattazzi, M.; Ferri, N. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) stimulates a procalcific response in chronic kidney disease (CKD). (December 2020) Authors: Lupo, M.G.; Faggin, E.; Rattazzi, M.; Garofalo, M.; Camera, M.; Poggio, P.; Ferri, N. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗